By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics announced today it has raised $1.75 million in a private placement, and is negotiating for another $1.25 million.

The $1.75 million was raised through the sale of senior secured debentures to an unnamed accredited investor. The debentures have a maturity date of Jan. 26, 2013 and accrue interest at 10 percent annually, payable semi-annually.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.